Loading
A phase 1/2 trial of STC-1010 + IS regimen + SOC therapy in colorectal cancer, run by Brenus Pharma, now recruiting.
First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT06934538 by Brenus Pharma, with 90 participants planned, started 2025-06-17 and due to reach its primary completion in 2028-06. Interventions recorded: STC-1010 + IS regimen + SOC therapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/